health biotech news today obesity drugs glp-1 Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine How Supply and Demand for
Description
doi: 10.1016/S0140-6736(08)61206-4 116 NorwoodPLiutkusJFHaberHPintileiEBoardmanMKTrautmannME
Calculate it
doi: 10.1016/j.tips.2012.03.014
[DOI] [PMC free article] [PubMed] [Google Scholar] 60.Mouhammad ZA, Rombaut A, Bermdez MYG, et al
"FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event" (Press release)
The main difference is administration
